B4813
BGP-15
≥98% (HPLC)
Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Cambia visualizzazione
| Taglio della confezione | SKU | Disponibilità | Prezzo |
|---|---|---|---|
| 5 mg | Per conoscere la disponibilità, visualizza il carrello | CHF 157.00 CHF 133.45 | |
| 25 mg | Per conoscere la disponibilità, visualizza il carrello | CHF 632.00 |
Informazioni su questo articolo
Formula empirica (notazione di Hill):
C14H22N4O2· 2HCl
Numero CAS:
Peso molecolare:
351.27
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
CHF 133.45
Prezzo di listinoCHF 157.00Risparmia il 15%Promozione valida solo online
Per conoscere la disponibilità, visualizza il carrello
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiQuality Level
assay
≥98% (HPLC)
form
solid
solubility
deionized water: 28 mg/mL
storage temp.
−20°C
SMILES string
Cl.Cl.N\C(=N/OCC(O)CN1CCCCC1)c2cccnc2
InChI
1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
InChI key
ISGGVCWFTPTHIX-UHFFFAOYSA-N
General description
BGP-15 is a hydroxylamine derivative, which has cytoprotective and neuroprotective properties. It reduces phospho- c-Jun N-terminal kinase (pJNK) and p38 stress signalling. BGP-15 also stimulates non-specific serine/threonine protein kinase (AKT) and insulin-like growth factor 1 receptor (IGFR1) protective signalling. BGP-15 functions as an insulin sensitizer in an olanzapine-induced metabolic disorder. It protects cells against cell death and enhances the expression of heat shock protein (HSP). BGP-15 might be used to treat heart failure (HF) and atrial fibrillation (AF).[1]
Application
BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins.
Biochem/physiol Actions
BGP-15 is PARP inhibitor, HSP72 activator.
BGP-15 is PARP inhibitor, HSP72 activator.
1 of 1
Questo articolo | |||
|---|---|---|---|
| form solid | form powder | form solid | form solid |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥95% (HPLC) | assay ≥98% (HPLC) |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. −20°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. room temp |
| solubility deionized water: 28 mg/mL | solubility DMSO: ≥20 mg/mL | solubility DMSO: 50 mg/mL | solubility deionized water: ≥5 mg/mL |
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
Classe di stoccaggio
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Disease-proportional proteasomal degradation of missense dystrophins
Talsness DM, et al.
Proceedings of the National Academy of Sciences of the USA, 112(40), 12414-12419 (2015)
BGP-15 prevents the death of neurons in a mouse model of familial dysautonomia
Ohlen SB, et al.
Proceedings of the National Academy of Sciences of the USA, 114(19), 5035-5040 (2017)
BGP-15 protects against oxidative stress-or lipopolysaccharide-induced mitochondrial destabilization and reduces mitochondrial production of reactive oxygen species
Sumegi K, et al.
PLoS ONE, 12(1), e0169372-e0169372 (2017)
Numero articolo commerciale globale
| SKU | GTIN |
|---|---|
| B4813-5MG | 04061833217597 |
| B4813-25MG | 04061833217580 |